Who are Capecitabine or gemcitabine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/capecitabine-or-gemcitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Capecitabine or gemcitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Capecitabine or gemcitabine (Capecitabine or gemcitabine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite chemotherapy agents. Area: Oncology.

phase 3 Antimetabolite chemotherapy agents Thymidylate synthase (capecitabine); Ribonucleotide reductase and DNA polymerase (gemcitabine) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Capecitabine or gemcitabine (Capecitabine or gemcitabine) — Centre Hospitalier Universitaire Dijon. Both capecitabine and gemcitabine are nucleoside analogs that inhibit DNA synthesis by interfering with nucleotide metabolism, leading to cancer cell death.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Capecitabine or gemcitabine TARGET	Capecitabine or gemcitabine	Centre Hospitalier Universitaire Dijon	phase 3	Antimetabolite chemotherapy agents	Thymidylate synthase (capecitabine); Ribonucleotide reductase and DNA polymerase (gemcitabine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite chemotherapy agents class)

Centre Hospitalier Universitaire Dijon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Capecitabine or gemcitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/capecitabine-or-gemcitabine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab